Novo Nordisk AS's biggest dilemma, according to chief scientific officer Mads Krogsgaard Thomsen, is how the company can position all of its diabetes products in the market to avoid cannibalization of the drugs and to ensure patients get the benefit of the best-suited treatment for their diabetes.
"We have a multitude of products for the same disease," Krogsgaard Thomsen told Scrip in a recent exclusive interview following...